Tonix Pharmaceuticals Holding Corp. (TNXP) shareholders
Close on Nov 17, 2026Market cap $50.42MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Sirenia Capital Management LP Joint filing with Alex Silverstein (8.80%) | 1,297,470 | 8.80% | 13G (passive) | Mar 31, 2026 |
| Point72 Asset Management, L.P. Joint filing with Point72 Capital Advisors, Inc. (9.20%), Steven A. Cohen (9.20%) | 1,235,058 | 9.20% | 13G (passive) | Dec 29, 2025 |
| Point72 Capital Advisors, Inc. Joint filing with Point72 Asset Management, L.P. (6.90%), Steven A. Cohen (6.90%) | 1,100,964 | 6.90% | 13G (passive) amendment | Mar 31, 2026 |
| Millennium Management LLC Joint filing with Millennium Group Management LLC (5.60%), Israel A. Englander (5.60%) | 890,366 | 5.60% | 13G (passive) | Jun 9, 2026 |
| AQR Capital Management Holdings, LLC Joint filing with AQR Capital Management, LLC (5.54%) | 882,595 | 5.54% | 13G (passive) | Jun 30, 2026 |
| BlackRock, Inc. | 854,579 | 6.70% | 13G (passive) amendment | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TNXP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 1,398,041 | 8.15% | $17.84M | +429,864 | 0.00% |
| Point72 Asset Management, L.P. | 1,166,752 | 6.80% | $14.89M | +1,041,338 | 0.02% |
| Millennium Management LLC | 966,932 | 5.64% | $12.34M | +747,259 | 0.00% |
| Aqr Capital Management LLC | 882,595 | 5.15% | $11.26M | +721,387 | 0.00% |
| Vanguard Capital Management LLC | 691,895 | 4.03% | $8.83M | +173,245 | 0.00% |
| Jones Hill Capital LP | 625,428 | 3.65% | $7.98M | +173,312 | 1.70% |
| Geode Capital Management, LLC | 395,260 | 2.30% | $5.04M | +81,969 | 0.00% |
| Ishara Investments LP | 338,250 | 1.97% | $4.32M | New | 3.17% |
| State Street Corp | 271,374 | 1.58% | $3.46M | +40,767 | 0.00% |
| UBS Group AG | 231,682 | 1.35% | $2.96M | +4 | 0.00% |
| Citadel Advisors LLC | 195,859 | 1.14% | $2.50M | −272,853 | 0.00% |
| Essex Investment Management Co LLC | 165,144 | 0.96% | $2.11M | New | 0.28% |
| Balyasny Asset Management L.P. | 132,591 | 0.77% | $1.69M | −180,491 | 0.00% |
| Northern Trust Corp | 120,386 | 0.70% | $1.54M | +20,252 | 0.00% |
| Nuveen, LLC | 117,447 | 0.68% | $1.50M | +22,886 | 0.00% |
| Vanguard Fiduciary Trust Co | 102,054 | 0.60% | $1.30M | +17,784 | 0.00% |
| Goldman Sachs Group Inc | 98,356 | 0.57% | $1.26M | +45,301 | 0.00% |
| Vanguard Portfolio Management LLC | 97,954 | 0.57% | $1.25M | +19,327 | 0.00% |
| FMR LLC | 93,551 | 0.55% | $1.19M | +91,813 | 0.00% |
| Ieq Capital, LLC | 92,373 | 0.54% | $1.18M | +78,015 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 102 | 9M | 54.6% | 28 / 51 | 8 / 5 | 5M | 0M |
| Q1 2026 | 81 | 5M | 28.4% | 20 / 31 | 16 / 8 | 3M | 1M |
| Q4 2025 | 70 | 4M | 21.8% | 17 / 34 | 9 / 7 | 2M | 0M |
| Q3 2025 | 60 | 2M | 13.8% | 18 / 23 | 9 / 5 | 1M | 0M |
| Q2 2025 | 47 | 1M | 8.1% | 27 / 10 | 6 / 5 | 1M | 0M |
| Q1 2025 | 25 | 0M | 2.8% | 24 / 0 | 1 / 1 | 0M | 0M |
| Q4 2024 | 2 | 0M | 0.0% | 2 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
100 funds held TNXP in Q2 2026, 67% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TNXP | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 488,108 | 2.85% | $6.23M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 389,931 | 2.27% | $4.98M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 187,414 | 1.09% | $2.39M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 158,829 | 0.93% | $1.59M | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 145,820 | 0.85% | $1.86M | 0.01% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 78,342 | 0.46% | $999.64K | 0.02% | Jun 30, 2026 |
| 1290 Essex Small Cap Growth Fund | 73,840 | 0.43% | $739.14K | 0.64% | Jul 31, 2026 |
| Vanguard Russell 2000 Index Fund | 69,338 | 0.40% | $854.94K | 0.00% | May 31, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 54,920 | 0.32% | $700.78K | 0.00% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 49,085 | 0.29% | $626.32K | 0.04% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 36,301 | 0.21% | $363.37K | 0.00% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 35,565 | 0.21% | $438.52K | 0.00% | May 31, 2026 |
| Nuveen Equity Index Fund | 31,079 | 0.18% | $311.10K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 29,354 | 0.17% | $374.56K | 0.01% | Jun 30, 2026 |
| AQR Small Cap Multi-Style Fund | 22,648 | 0.13% | $288.99K | 0.08% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Seth Lederman | Chief Executive Officer, Director | 36,007 | 0.21% | Nov 12, 2026 |
| Thomas Englese | Chief Commercial Officer | 694 | 0.00% | Sep 8, 2026 |
| Bradley Saenger | Chief Financial Officer | 2,154 | 0.01% | Jul 9, 2026 |
| Siobhan Fogarty | Chief Technology Officer | 1 | 0.00% | Feb 26, 2026 |
| Gregory M. Sullivan | Chief Medical Officer | 0 | – | Feb 26, 2026 |
| Jessica Edgar Morris | Chief Operating Officer | 0 | – | Feb 26, 2026 |
| Richard H. Bagger | Director | 1,000 | 0.01% | Aug 24, 2026 |
| Carolyn E. Taylor | Director | 1,833 | 0.01% | Jun 15, 2026 |
| Richard Newcomb Stillwell | Director | 5,000 | 0.03% | Jun 9, 2026 |
| James Randolph Hunter Jr | Director | – | – | May 14, 2026 |
| Adeoye Y. Olukotun | Director | 0 | – | May 14, 2026 |
| Margaret Smith Bell | Director | 0 | – | May 14, 2026 |
| David L. Grange | Director | – | – | May 14, 2026 |
| James Treco | Director | 250 | 0.00% | May 14, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Seth Lederman Chief Executive Officer, Director | Nov 11, 2026 | Buy | +5,000 | $4.05 | $20.28K | 16,005 |
| Seth Lederman Chief Executive Officer, Director | Aug 27, 2026 | Buy | +2,000 | $13.79 | $27.58K | 11,005 |
| Richard H. Bagger Director | Aug 20, 2026 | Buy | +1,000 | $12.60 | $12.60K | 1,000 |
| Bradley Saenger Chief Financial Officer | Jun 30, 2026 | Other | +1,453 | $10.91 | $15.85K | 2,154 |
| Carolyn E. Taylor Director | Jun 12, 2026 | Buy | +1,415 | $10.55 | $14.93K | 1,833 |
| Seth Lederman Chief Executive Officer, Director | Jun 9, 2026 | Buy | +5,000 | $11.79 | $58.95K | 9,005 |
| Richard Newcomb Stillwell Director | Jun 8, 2026 | Buy | +5,000 | $11.65 | $58.25K | 5,000 |
| Seth Lederman Chief Executive Officer, Director | Mar 31, 2026 | Buy | +5,000 | $12.62 | $63.10K | 20,001 |
| Seth Lederman Chief Executive Officer, Director | Mar 18, 2026 | Buy | +15,000 | $14.89 | $223.35K | 15,001 |
| Bradley Saenger Chief Financial Officer, 10% owner | Dec 31, 2025 | Award | +701 | $13.42 | $9.41K | 701 |
| Carolyn E. Taylor Director | Aug 21, 2025 | Buy | +418 | $36.03 | $15.06K | 418 |
| James Treco Director | Aug 20, 2025 | Buy | +250 | $36.00 | $9.00K | 250 |
| Seth Lederman Chief Executive Officer, Director | May 15, 2025 | Buy | +4,000 | $21.55 | $86.20K | 4,005 |
| Margaret Smith Bell Director | Feb 5, 2025 | Other | −1 | $0.15 | $0 | 0 |
| James Treco Director | Feb 5, 2025 | Other | −0.02 | $0.30 | $0 | 0 |
| Richard H. Bagger Director | Feb 5, 2025 | Other | −0.02 | $0.20 | $0 | 0 |
| Gregory M. Sullivan Chief Medical Officer | Feb 5, 2025 | Other | −0.11 | $1.47 | $0 | 0 |
| Jessica Edgar Morris Chief Operating Officer | Feb 5, 2025 | Other | −1 | – | – | 0 |
| Bradley Saenger Chief Financial Officer | Feb 5, 2025 | Other | −0.04 | – | – | 0 |
| Seth Lederman Chief Executive Officer, Director | Feb 5, 2025 | Other | −0.22 | $3.30 | $1 | 1 |
| Seth Lederman Chief Executive Officer, Director | Feb 5, 2025 | Other | −5.18 | $3.38 | $18 | 5 |
| Seth Lederman Chief Executive Officer, Director | Feb 5, 2025 | Other | −1 | $0.15 | $0 | 0 |
| Adeoye Y. Olukotun Director | Jun 10, 2024 | Other | −0.81 | $1.91 | $2 | 0 |
| Seth Lederman Chief Executive Officer, Director | Jun 29, 2022 | Buy | +20,000 | $1.71 | $34.20K | 24,235 |
| Seth Lederman Chief Executive Officer, Director | Mar 25, 2022 | Buy | +100,000 | $0.25 | $25.00K | 112,177 |
| Seth Lederman Chief Executive Officer, Director | Sep 28, 2021 | Buy | +12,000 | $0.61 | $7.32K | 12,177 |
| Bradley Saenger Chief Financial Officer | Jun 30, 2021 | Award | +18,248 | $0.58 | $10.58K | 19,645 |
| Gregory M. Sullivan Chief Medical Officer | Jun 30, 2021 | Award | +36,496 | $0.58 | $21.17K | 99,223 |
| Daniel Wintner Goodman Director | May 25, 2021 | Buy | +5,000 | $1.12 | $5.60K | 5,001 |
| Seth Lederman Chief Executive Officer, Director | Mar 24, 2021 | Buy | +16,733 | $1.32 | $22.09K | 135,000 |
| Gregory M. Sullivan Chief Medical Officer | Jan 7, 2021 | Award | +41,322 | $0.51 | $21.07K | 62,727 |
| Seth Lederman Chief Executive Officer, Director | Dec 30, 2020 | Buy | +35,000 | $0.68 | $23.80K | 118,267 |
| James Treco Director | Aug 31, 2020 | Buy | +5,500 | $0.89 | $4.90K | 10,000 |
| Margaret Smith Bell Director | Aug 20, 2020 | Buy | +5,391 | $0.93 | $5.01K | 5,391 |
| Gregory M. Sullivan Chief Medical Officer | Aug 17, 2020 | Buy | +20,000 | $1.03 | $20.60K | 21,405 |
| James Treco Director | Aug 14, 2020 | Buy | +4,500 | $1.06 | $4.77K | 4,500 |
| Adeoye Y. Olukotun Director | Aug 13, 2020 | Buy | +5,350 | $0.94 | $5.03K | 5,350 |
| Richard H. Bagger Director | Aug 13, 2020 | Buy | +10,000 | $0.91 | $9.10K | 10,000 |
| Seth Lederman Chief Executive Officer, Director | Aug 13, 2020 | Buy | +60,000 | $0.91 | $54.60K | 83,267 |
| Bradley Saenger Chief Financial Officer | Jan 6, 2020 | Award | +493 | $1.02 | $503 | 1,397 |
| Seth Lederman Chief Executive Officer, Director | Dec 3, 2019 | Buy | +20,000 | $1.16 | $23.20K | 23,267 |
| Gregory M. Sullivan Chief Medical Officer | Jul 31, 2019 | Award | +1,142 | $11.82 | $13.50K | 1,405 |
| Bradley Saenger Chief Financial Officer | Jul 31, 2019 | Award | +815 | $11.82 | $9.63K | 904 |
| Seth Lederman Chief Executive Officer, Director | Mar 29, 2019 | Buy | +5,000 | $2.49 | $12.45K | 32,670 |
| Seth Lederman Chief Executive Officer, Director | Mar 26, 2019 | Buy | +25,000 | $2.38 | $59.50K | 27,670 |
| Gregory M. Sullivan Chief Medical Officer | Feb 17, 2019 | Award | +59 | $17.85 | $1.05K | 1,405 |
| Bradley Saenger Chief Financial Officer | Feb 17, 2019 | Award | +59 | $17.85 | $1.05K | 904 |
| Seth Lederman Chief Executive Officer, Director | Jun 29, 2018 | Buy | +500 | $4.64 | $2.32K | 17,666 |
| Seth Lederman Chief Executive Officer, Director | Jun 28, 2018 | Buy | +500 | $4.58 | $2.29K | 17,166 |
| Seth Lederman Chief Executive Officer, Director | Jun 27, 2018 | Buy | +500 | $4.55 | $2.28K | 16,666 |
| Ernest Mario Director | Jun 25, 2018 | Buy | +16,500 | $4.48 | $73.92K | 50,000 |
| Gregory M. Sullivan Chief Medical Officer | Jun 14, 2018 | Buy | +10,000 | $3.97 | $39.70K | 20,482 |
| Bradley Saenger Chief Financial Officer | Jun 14, 2018 | Buy | +300 | $4.10 | $1.23K | 3,079 |
| Jessica Edgar Morris Chief Operating Officer | Jun 14, 2018 | Buy | +300 | $4.19 | $1.26K | 1,638 |
| Seth Lederman Chief Executive Officer, Director | Jun 12, 2018 | Buy | +2,000 | $4.37 | $8.74K | 20,463 |
| Seth Lederman Chief Executive Officer, Director | Jun 12, 2018 | Buy | +1,000 | $4.37 | $4.37K | 16,166 |
| John B. Rhodes Director | Jun 1, 2018 | Buy | +7,500 | $3.33 | $24.98K | 23,470 |
| Seth Lederman Chief Executive Officer, Director | May 25, 2018 | Buy | +4,000 | $3.17 | $12.68K | 26,700 |
| Charles E. Mather Iv Director | Feb 27, 2018 | Option exercise | +750 | – | – | 12,580 |
| Ernest Mario Director | Feb 9, 2018 | Gift | +10,000 | – | – | 33,500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Tonix Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 24,705 shares on Aug 21, 2026 over the last 90 days.
See a number that looks wrong?